Where science, technology, and expertise meet

Our founders are molecular biologists, research physicians, and IT specialists who have been working since the turn of the millennium on uncovering the genetic background of cancer and on developing complex, highly intricate healthcare IT systems. They built their professional knowledge in leading centers such as Houston, Strasbourg, Paris, and Heidelberg, where they dealt with the genetic, clinical, and data processing issues of malignant diseases.

The group was also joined by experts skilled in archaeological genetics, who gained unique experience in the examination of very small amounts of low-quality DNA. This multidisciplinary background established the molecular diagnostic and bioinformatic competence on which ELT’s work rests today.

We laid our professional foundations after the turn of the millennium, at the dawn of molecular tumor diagnostics, by establishing collaborations that form the backbone of our company's current operations. We recognized that cutting-edge research, practical application opportunities, and the medical professional background can together form a strong alliance.

Our founders and specialists began working on the examination of nucleic acids circulating in the blood early on, alongside the first wave of the international research community; our personal meeting with Dennis Lo, the pioneer of fetal molecular genetic diagnostics, was decisive in this.

Enterprise Group Technologies, the legal successor of Siemens Enterprise and one of the founders of European Life Technologies, entered the domestic healthcare IT market (HIS) with one of the leading Hungarian-developed hospital information systems (EMMA). This represents unique experience in the fields of critical data security, large-volume healthcare data management, and the development of intuitive, fast, highly complex systems. This period enabled us to deeply understand the language of the medical profession and the real clinical needs for diagnostic decision-support systems.

Market product development started in 2017, when renowned European professional investors and leading Hungarian companies in their fields joined forces to create liquid biopsy solutions such as our BC-Monitor product, which was later introduced to the market. The 1.5 billion HUF European Union grant enabled an R&D infrastructure that is outstanding even by international standards.

By unifying imaging, IT, and molecular diagnostics, we created our comprehensive, future-proof vision. We first presented Enterprise oncoAId™, this innovative framework, to the broad professional audience at the 2019 congress of the Hungarian Hospital Association, designating the new oncological directions of „the hospital of the future.” Already at that time, Enterprise genoAId™ — our bioinformatic platform based on Directed Acyclic Graphs (DAG) using WDL for analyzing next-generation sequencing data — was an integral part of it.

At the end of December, we founded European Life Technologies (ELT) Hungary Kft. for the practical and market exploitation of the results of many years of research and development. With this step, we appeared on the domestic and international markets as a dedicated company covering the full spectrum of solid tumor genetic diagnostics.

Recognizing the growing international market demands and the complex value embedded in our technology, our company was transformed into a public limited company (Zrt.). This structural transformation created the stable legal, organizational, and economic environment necessary for global expansion through the joining of additional professional and financial investors, and provided the opportunity to prepare the company for a stock market presence. In parallel, our genosmart DX (GSDX) complex process management system was also introduced, providing a professional user interface and framework for the standardized display of test orders, analyses, and data, as well as for research work.

The conscious building of our presence on the Indonesian market began, and our first major international investors also arrived. In parallel — building on previous successes — the productization and market launch of PC-Alarm, our unique urine-based cancer detection innovation, also started.

With the joining of additional investors, our company's equity already exceeded 4 billion HUF. Our international network of relationships was strengthened by high-level diplomatic visits, thereby supporting our Asian collaborations, including with the Indonesian Ministry of Health and the Dharmais Indonesian National Cancer Center Hospital.

We presented to Mr. Budi Gunadi Sadikin, Indonesian Minister of Health, the 'Lighthouse' model envisioned and built by ELT experts, which builds on local social, cultural and geographical characteristics, and supports Indonesia's fight against cancer and the faster, more accurate, and more effective recovery of patients through the establishment of a national liquid biopsy center. In connection with the joint scientific project launched in March, the need has already arisen for the longitudinal continuation of the studies and the broad introduction of diagnostic tests into practice as soon as possible.